Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine
Psyence BioMed's Texas subsidiary TIRC signed a manufacturing services agreement with Benuvia Operations for planned U.S. production of pharmaceutical-grade ibogaine API under cGMP standards. Benuvia operates an 83,000-square-foot DEA-registered facility in Round Rock, Texas, and says it holds roughly half of the U.S. ibogaine production quota; import permit and quota applications are being advanced with the DEA.
Key figures
- Drug Name
- ibogaine API
- Facility size sqft
- 83000
- Benuvia ibogaine quota share
- approximately half of U.S. aggregate production quota
- Definitive agreement deadline
- November 30, 2026
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.